Enhanced delivery of lopinavir to the CNS using Compritol ®-based solid lipid nanoparticles

Therapeutic Delivery

Volumn 2, Issue 1, 2011, Pages 25-35

  Alex, Aji ^a   Paul, Willi ^b   Chacko, A J ^a   Sharma, Chandra P ^b  

^a MAHATMA GANDHI UNIVERSITY   (India)

^b SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; GLYCEROL BEHENATE; LOPINAVIR; POLOXAMER; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAMAN SPECTROMETRY; RAT; SINGLE DRUG DOSE; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

EID: 79954567170     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.96     Document Type: Article

References (27)

1. Bagasra OE, Lavi L, Bobroski K, et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 10, 573-585(1996).
2. Chen H, Wood C, Petito CK. Comparisons of HIV-1 viral sequences in brain, choroid plexus and spleen: potential role of choroid plexus in the pathogenesis of HIV encephalitis. J. Neuro. Virol. 6, 498-506 (2000). (Pubitemid 32098064)
3. González-Scarano F, Martín-García J. The neuropathogenesis of AIDS. Nature Rev. Immunol. 5, 69-81 (2005). (Pubitemid 40070332)
4. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 63, 769-802 (2003). (Pubitemid 36432083)
5. Wong HL, Chattopadhyay N, Wu XY, et al. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv. Drug Deliv. Rev. 62, 503-517 (2010).
6. Varatharajan L, Thomas SA. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 82, A99-A109 (2009).
7. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Inter. J. Pharma. 298, 274-292 (2005). (Pubitemid 40910731)
8. Göppert TM, Müller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J. Drug Targ. 13, 179-187 (2005). (Pubitemid 40668171)
9. Müller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 50, 161-177 (2000). (Pubitemid 30326695)
10. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J. Cont. Rel. 127, 97-109 (2008).
11. Jee JP, Lim SJ, Park JS, Kim CK. Stabilization of all-trans retinol by loading lipophilic antioxidants in solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 63, 134-139 (2006).
12. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93-102 (2006). (Pubitemid 41773257)
13. Lenaerts V, Labib A, Chouinard F, et al. Nanocapsules with a reduced liver uptake: targeting of phthalocyanines to EMT-6 mouse mammary tumour in vivo. Eur. J. Pharm. Biopharm. 41, 38-43 (1995).
14. Usami Y, Oki T, Nakai M, et al. Simple HPLC method for the simultaneous determination of lopinavir, ritonavir and Efavirenz. Chem. Pharm. Bull. 51, 715-718 (2003). (Pubitemid 41672737)
15. Nirogi R, Kandikere V, Mudigonda K, et al. A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system. J. Neurosci. Methods 178, 116-119 (2009).
16. Kumar GN, Jayanti VK, Johnson MK, et al. Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm. Res. 21, 1622-1630 (2004). (Pubitemid 41184393)
17. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42, 3218-3224 (1998). (Pubitemid 28553744)
18. Kreuter J. Colloidal Drug Delivery Systems. Marcel Dekker, NY, USA (1994).
19. Paliwal R, Rai S, Vaidya B, et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine 5, 184-191 (2009).
20. Vyas SP. Lymphatics: drug targeting and transportation. In: Controlled and Novel Drug Delivery. Jain NK (Ed.). CBS Publishers & Distributors. New Delhi, India 169-183 (1997).
21. Porter CJH, Charman WN. Intestinal lymphatic drug transport: an update. Adv. Drug Deliv. Rev. 50, 61-80 (2001). (Pubitemid 32727277)
22. Jani P, Halbert GW, Langridge J, Florence AT. The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol. 41, 809-812 (1989). (Pubitemid 20112141)
23. Shakweh M, Ponchel G, Fattal E. Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin. Drug Deliv. 1, 141-163 (2004). (Pubitemid 40297962)
24. Hoet PH, Brüske-Hohlfeld I, Salata OV. Nanoparticles-known and unknown health risks. J. Nanobiotechnol. 2, 12-27 (2004).
25. Borm PJ, Robbins D, Haubold S, et al. The potential risks of nanomaterials: a review carried out for ECETOC. Part. Fibre Toxicol. 3, 11-46 (2006).
26. Tröster SD, Müller U, Kreuter J. Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 61, 85-100 (1990). (Pubitemid 20201609)
27. Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome p-450 3a-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab. Dispos. 27, 902-908 (1999). (Pubitemid 29347590)